Eslicarbazepine acetate

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

2009

www.ebi.ac.uk

First approval year: 2009
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Eslicarbazepine acetate
www.ebi.ac.uk

Molecular weight: 296.33
www.ebi.ac.uk

Structure (SMILES): CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21
www.ebi.ac.uk

aptiom
Aptiom
erelib
Erelib
exalief
Exalief
pazzul
Pazzul
stedesa
Stedesa
zebinix
Zebinix

bia 2 093
BIA 2-093
BIA 2-093 - 1800 mg (Group 1)
BIA 2-093 - 2400 mg (Group 2)
BIA 2-093 900 mg (Part I)
bia 2093
BIA-2-093
BIA-2093
eslicarbazepine acetate
Eslicarbazepine acetate
ESLICARBAZEPINE ACETATE [EMA EPAR]
ESLICARBAZEPINE ACETATE [MART.]
ESLICARBAZEPINE ACETATE [MI]
ESLICARBAZEPINE ACETATE [ORANGE BOOK]
ESLICARBAZEPINE ACETATE [USAN]
ESLICARBAZEPINE ACETATE [VANDF]
Eslicarbazepine acetate [WHO-DD]
eslicarbazepine acetate ema epar
eslicarbazepine acetate mart
eslicarbazepine acetate mi
eslicarbazepine acetate orange book
eslicarbazepine acetate usan
eslicarbazepine acetate vandf
eslicarbazepine acetate who dd
SEP - 0002093

And 8 more, listed on the interactive page.

ATC classification codes

N03AF04

CAS registry numbers

236395-14-5

ChEMBL ID: CHEMBL87992
www.ebi.ac.uk

InChIKey: QIALRBLEEWJACW-INIZCTEOSA-N
www.ebi.ac.uk

PubChem compound IDs

179344

RxNorm IDs (RxCUI)

1482501

FDA ingredient codes (UNII)

BEA68ZVB2K

Applicant: SUMITOMO PHARMA AM
Approval date: 8 Nov 2013
Application number: NDA022416

Status: Authorised
Status date: 21 Apr 2009
Authorisation date: 21 Apr 2009
Approved indications: Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.
Product number: EMEA/H/C/000988
Authorisation holder: BIAL - Portela & Ca, S.A.
Priority medicines scheme: No
Generic: No
Biosimilar: No
Generic medicines: 0
Biosimilar medicines: 0
Advanced therapy: No
Conditional approval: No
Additional monitoring: No
Accelerated assessment: No
Exceptional circumstances: No

Therapeutic areas

Epilepsy

European medicines record

www.ema.europa.eu

Patents: 7
Designations: 0
Earliest recorded loss of exclusivity: 24 Aug 2032
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: No
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only

Drug name stem: -pine

Administration routes

Oral

Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
P35498
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
P35499
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q01118
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q14524
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q15858
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q99250
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q9NY46
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q9UI33
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q9UQD0
Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit
Protein identifier
Q9Y5Y9

Open Targets mechanisms

Mechanism
Sodium channel alpha subunit blocker
Action type
Blocker
Target
Sodium channel alpha subunit

DrugCentral mechanisms

Action type
Blocker
Gene symbol
SCN1A|SCN4A|SCN7A|SCN5A|SCN9A|SCN2A|SCN3A|SCN11A|SCN8A|SCN10A
Protein identifier
P35498|P35499|Q01118|Q14524|Q15858|Q99250|Q9NY46|Q9UI33|Q9UQD0|Q9Y5Y9
Organism
Homo sapiens
Target development level
Tclin|Tbio|Tchem|NA

Condition
Epilepsy
Highest recorded phase
4
Condition identifier
EFO:0000474
Subject identifier
D004827
Condition
Epilepsies, Partial
Highest recorded phase
3
Condition identifier
EFO:0004263
Subject identifier
D004828
Condition
Fibromyalgia
Highest recorded phase
2
Condition identifier
EFO:0005687
Subject identifier
D005356
Condition
Neuralgia
Highest recorded phase
1
Condition identifier
EFO:0005762
Subject identifier
D009437
Condition
Bipolar Disorder
Highest recorded phase
2
Condition identifier
EFO:0009963
Subject identifier
D001714
Condition
Diabetic Neuropathies
Highest recorded phase
3
Condition identifier
EFO:1000783
Subject identifier
D003929
Condition
Epilepsy, Complex Partial
Highest recorded phase
3
Condition identifier
EFO:1000877
Subject identifier
D017029
Condition
Epilepsy
Highest recorded phase
4
Condition identifier
HP:0001250
Subject identifier
D004827
Condition
Seizures
Highest recorded phase
4
Condition identifier
HP:0001250
Subject identifier
D012640
Condition
Migraine Disorders
Highest recorded phase
2
Condition identifier
MONDO:0005277
Subject identifier
D008881
Condition
Neuralgia, Postherpetic
Highest recorded phase
3
Condition identifier
MONDO:0041052
Subject identifier
D051474

Condition identifier
EFO_0000474
Condition identifier
EFO_0004263
Highest recorded phase
3
Condition identifier
EFO_0005687
Highest recorded phase
2
Condition identifier
EFO_0005762
Highest recorded phase
1
Condition identifier
EFO_0009963
Highest recorded phase
2
Condition identifier
EFO_1000783
Highest recorded phase
3
Condition identifier
EFO_1000877
Highest recorded phase
3
Condition identifier
HP_0001250
Condition identifier
HP_0001250
Highest recorded phase
4
Condition identifier
HP_0002384
Highest recorded phase
3
Condition identifier
HP_0007359
Highest recorded phase
3
Condition identifier
MONDO_0005027
Highest recorded phase
4
Condition identifier
MONDO_0005277
Highest recorded phase
2
Condition identifier
MONDO_0005384
Highest recorded phase
3
Condition identifier
MONDO_0005546
Highest recorded phase
2
Condition identifier
MONDO_0006626
Highest recorded phase
2
Condition identifier
MONDO_0041052
Highest recorded phase
3

Event
acute pulmonary oedema
Reports
8
Reporting signal score
20.4632
Event
blood sodium decreased
Reports
10
Reporting signal score
18.7794
Event
confusional state
Reports
19
Reporting signal score
11.1903
Event
diplopia
Reports
9
Reporting signal score
13.0767
Event
drug dose titration not performed
Reports
20
Reporting signal score
105.236
Event
drug reaction with eosinophilia and systemic symptoms
Reports
14
Reporting signal score
20.358
Event
ectopic kidney
Reports
2
Reporting signal score
9.55522
Event
epilepsy
Reports
9
Reporting signal score
10.0209
Event
generalised tonic-clonic seizure
Reports
16
Reporting signal score
35.3358
Event
hyponatraemia
Reports
68
Reporting signal score
154.253
Event
hyponatraemic seizure
Reports
3
Reporting signal score
12.9354
Event
irritability
Reports
15
Reporting signal score
18.4843
Event
labelled drug-drug interaction medication error
Reports
6
Reporting signal score
10.8486
Event
mitral valve disease
Reports
8
Reporting signal score
30.9715
Event
muscle rigidity
Reports
6
Reporting signal score
9.61189
Event
myocarditis
Reports
8
Reporting signal score
16.3123
Event
partial seizures
Reports
5
Reporting signal score
10.7883
Event
partial seizures with secondary generalisation
Reports
5
Reporting signal score
22.8801
Event
petit mal epilepsy
Reports
4
Reporting signal score
8.55633
Event
posturing
Reports
3
Reporting signal score
11.3958
Event
psychomotor skills impaired
Reports
8
Reporting signal score
26.0435
Event
rash maculo-papular
Reports
8
Reporting signal score
8.66651
Event
seizure
Reports
151
Reporting signal score
454.063
Event
simple partial seizures
Reports
5
Reporting signal score
20.5554
Event
somnolence
Reports
28
Reporting signal score
23.5267

And 3 more, listed on the interactive page.

NCT00866775
clinicaltrials.gov
NCT00900237
clinicaltrials.gov
NCT00957047
clinicaltrials.gov
NCT00957372
clinicaltrials.gov
NCT00957684
clinicaltrials.gov
NCT00988156
clinicaltrials.gov
NCT00988429
clinicaltrials.gov
NCT01527513
clinicaltrials.gov
NCT00910247
clinicaltrials.gov
NCT00987558
clinicaltrials.gov
NCT01091662
clinicaltrials.gov
NCT01162460
clinicaltrials.gov
NCT01422720
clinicaltrials.gov
NCT01678976
clinicaltrials.gov
NCT01679002
clinicaltrials.gov
NCT01878578
clinicaltrials.gov
NCT01879332
clinicaltrials.gov
NCT01879345
clinicaltrials.gov
NCT02170064
clinicaltrials.gov
NCT02170077
clinicaltrials.gov
NCT02170649
clinicaltrials.gov
NCT02171195
clinicaltrials.gov
NCT02171234
clinicaltrials.gov
NCT02172742
clinicaltrials.gov
NCT02172755
clinicaltrials.gov

And 29 more, listed on the interactive page.

Dose: 400 mg
Route: Oral
How often: Once daily

Conditions of use

Take with or without food

Hydrogen bond acceptors: 3
Hydrogen bond donors: 1
Polar surface area: 72.63
Calculated partition coefficient (ALogP): 3.06
Calculated partition coefficient (XLogP): 2
Prodrug: Yes
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 1
Heavy atoms: 22
Molecular formula: C17H16N2O3
Monoisotopic mass: 296.11609238
Natural product: Yes

13668-538
13668-539
13668-540
13668-541
31722-428
31722-429
31722-430
31722-431
43598-684
43598-685
43598-686
43598-687
51407-779
51407-780
51407-781
51407-782
59651-533
59651-534
59651-535
59651-536
59746-717
59746-718
59746-719
59746-720
63402-202

And 16 more, listed on the interactive page.

Recorded assays: 296
Active assays: 3

Confirmatory
Other

Anticonvulsants
id.nlm.nih.gov
Voltage-Gated Sodium Channel Blockers
id.nlm.nih.gov

Related records

Trials (146)

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty
A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093
A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501
A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants
A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate
A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug
A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate
A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093
A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)
A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers
A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

Approved for (2)

Epilepsy
Visual epilepsy

In development for (8)

Bipolar depression Phase 2
Complex partial epilepsy Phase 3
Diabetic neuropathy Phase 3
Fibromyalgia Phase 2
Focal epilepsy Phase 3
Migraine disorder Phase 2
Neuralgia Phase 1
Postherpetic neuralgia Phase 3

Targets (10)

SCN10A Sodium channel alpha subunit blocker
SCN11A Sodium channel alpha subunit blocker
SCN1A Sodium channel alpha subunit blocker
SCN2A Sodium channel alpha subunit blocker
SCN3A Sodium channel alpha subunit blocker
SCN4A Sodium channel alpha subunit blocker
SCN5A Sodium channel alpha subunit blocker
SCN7A Sodium channel alpha subunit blocker
SCN8A Sodium channel alpha subunit blocker
SCN9A Sodium channel alpha subunit blocker

Eslicarbazepine acetate

Development status

Names and chemistry

Brand names (12)

Other names (33)

Identifiers

Regulatory information

United States

European Union

Therapeutic areas

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (10)

Open Targets mechanisms

DrugCentral mechanisms

Investigated indications (11)

Open Targets indications (17)

Reported adverse events (28)

Trial references (54)

Dosing

Conditions of use

Chemical properties

National Drug Codes

Evidence counts

Active assay types (2)

Pharmacologic actions

Related records

Trials (146)

Approved for (2)

In development for (8)

Targets (10)